A 61-year-old man with pulmonary aspergilloma received two antifungals intracavitarily. Although clinical, serological and roentgenographic improvement were observed with fluconazole therapy, bronchial secretions continuously yielded Aspergillusfumigatus. Whenfluconazole was switched to amphotericin B, the pathogen was eradicated immediately. The minimal inhibitory concentrations (MICs) of the isolate were 400 jig/ml for fluconazole, and 0.2 jag/ml for amphotericin B. Although the discrepancy between in vitro and in vivo efficacy of antifungals has been argued, it was suggested the drug of choice should be selected on the basis of the MICresults at least in the intracavitary antifungal therapy for pulmonary aspergilloma. (Internal Medicine 34: 85-88, 1995) 
Introduction
Pulmonary aspergilloma generally develops in a pre-existing destroyed lung compartment, for example, residual cavities occurring with tuberculosis, sarcoidosis, bronchiectasis orpostoperational dead spaces (1 , 2) . Unlike other types of aspergillosis, aspergilloma is characterized by saprophytic growth of the Aspergillus species. Amongseveral therapeutic modalities for this entity, intracavitary administration of antifungals is expected to be effective (3) . However, the drug of choice as well as the appropriate dosages remain controversial. For this reason, a standard method for antifungal susceptibility testing has not been established, and a major difference between in vitro and in vivo activities (4, 5) usually exists.
Case Report A 6 1 -year-old man complaining ofa cough and hemosputum was referred to our hospital on December 6, 1991. A diagnosis of silicosis hadbeen established atthe age of48, and he hadbeen treated for pulmonary tuberculosis complicated by silicosis for 9 years. On admission, a chest X-ray revealed a thickened cavitary wall ofa healed tuberculous lesion in the left upper lobe (Fig. 1) . On computed tomogram, a cavitary lesion with a partially thickened inner wall in left S1+2 was demonstrated (Fig. 2a) . Neither calcification in the lesion nor adjacent soft tissue involvement were shown. Physically, a few swollen neck lymph nodes, accentuated second heart sound and low body weight were observed.
In laboratory examinations (Table 1 ) , the erythrocyte sedimentation rate, C-reactive protein and serum gammaglobulin showed increases, and Aspergillus precipitin was positive (32 x). Transbronchial lung biopsy (TBLB) through left B1+2 revealed neither fungal tissue invasion nor malignancy. Tumor markers including carcinoembryonic antigen, squamous cell carcinoma antigen, carbohydrate antigen 19-9 and neuronspecific enolase were all within the normal limits, and the cytology of both expectorated and endobronchial sputum were negative. Aspergillus fumigatus was isolated from endobronchial sputum and bronchial lavage of left B1+2. Fromthese radiological and laboratory findings, the diagnosis of pulmonary aspergilloma with no typical fungus ball was established. An approach to avoid a serious complication such as major hemoptysis was necessary. Becauseof intolerance to surgical resection due to poor pulmonaryreserve, percutaneous intracavitary treatment with antifungals was selected. To determine a safe insertion site, bronchial, intercostal and intrathoracic arteries were examinedangiographically. Withthe consent of the patient, an 1 8-F silicone catheter with a three-way stopcock was introduced through the first intercostal space on the left anterior chest wall into the cavity. No major complication developed during the procedure.
On December 20, 1991 , treatment with fluconazole (FCZ, 1,000 jug/ml) was commenced at a dosage of 10 mg/day, and was gradually increased to 30 mg/day (Fig. 3) . From day 10 of the therapy, the cough and hemosputum decreased, and improvement in C-reactive protein and roentgenographic findings (Fig. 2b) were observed. However, the same amount of Aspergilli was repeatedly recovered from expectorated sputum as the total dosage of FCZ reached 1,090 mg.
Treatment with amphotericin B (AMPH, 1,000 jig/ml) began on February 13, 1992, at a dosage of 10 mg/day. Seven days later, the bronchial secretion became sterile, and AMPH therapy was completed with a total dosage of 660 mg. The serum Aspergillus precipitin turned negative in May 1992. No adverse reaction associated with this treatment wasobserved throughout the therapeutic course. The patient has since been treated with aerosolized AMPH, and the culture has continuously remained sterile.
An antifungal susceptibility test was performed using a broth dilution method (6) . Namely, 104 conidia were incubated at 30°C for 24 hours in glass tubes containing serially diluted antifungal agents dissolved in YMbroth (0.3% malt extract, 0.3% yeast extract, 0.3% polypeptone and 2% dextrose, prepared in 1/15 Mphosphate buffered saline [pH=7.0]). The MIC was determined visually to be the lowest concentration inhibiting significant mycelial growth. The MICvalues of the isolate recovered at the time of admission were 400 jug/ml for FCZ, and 0.2 jug/ml for AMPH.
Discussion
The minority of the patients with pulmonary aspergilloma lack a typical mycetomain the cavity. For this explanation, an aspergilloma develops as a lining on the pre-existing cavity at its early stage, then shows partial growth and finally separates from the cavity wall appearing as a fungus ball (2). As for differential diagnosis in the present case, chronic necrotizing aspergillosis was required to be ruled out. It was not compatible in this case because; 1) tissue invasion by fungal elements was not demonstrated in the TBLBspecimen, 2) there was no newly developing infiltration on the chest X-ray, 3) the serum aspergillus antigen presence was negative, and 4) systemic symptoms and radiological findings were improved only by topical antifungal s. Topical treatment of aspergilloma is indicated for patients with poor pulmonary reserve. High therapeutic efficacy reports for this treatment, range from 41.7% to 100% (3, 7-9). Antifungals are instilled either percutaneously or endobronchially. The former approach has some advantages in that drugs can be administered more reliably, and the patient's suffering as well as the therapy course can be reduced. On the other hand, this
Intracavitary Treatment for Aspergilloma method is limited almost exclusively to lesions contiguous to the chest wall, an angiography is required to avoid massive bleeding, and other complications including pneumothorax, subcutaneous emphysemaand infection might occur. In the present case, there were no problems except for minor hemosputum during the insertion procedure, which required no medication. Weselected fluconazole (FCZ) as the first antifungal to be given, expecting relatively fewer adverse reactions than amphotericin B (AMPH) and efficacy based on MIC results. As for therapeutic efficacy, we believe that the pathogen wascompletelyeradicated since the cultures wererepeatedly negative.
The MICtests of the isolated aspergilli from this patient provided an interesting result. It has been known that, in vitro activity ofantifungals does not predict in vivo efficacy due to the problems associated with pharmacokinetics or with host immunity (5, 10) . Furthermore, the interpretation of the MIC data is still controversial, because a standard method of antifungal susceptibility testing has not yet been made available. Therefore, the drug of choice can notbe determined solely on the basis of MICs.
In the present case, however, the intact epithelial lining of the cavity was supposed to be hardly maintained (2), the fungal elements seemed to exist almost free from topical host defense and, in addition, the drug was directly instilled. Therefore, it might be assumed that the relation between the fungi and antifungals in this patient was comparable to the in vitro setting, if so, the results of the mycologic examinations were fully reasonable. Namely, real concentrations of administered FCZ and AMPHwere both 1 ,000 jig/ml, and the MICs for FCZ and AMPHwere 400 jig/ml and 0.2 jug/ml, respectively. Accordingly, the FCZ therapy brought clinical improvement but did not eradicate the fungi completely, while the AMPHshowed a prompt and excellent mycologic effect. In terms of antifungal activity, itraconazole, a newly developed triazole with an MIC of 0.05 jug/ml, is also considered to be a promising agent in this therapeutic modality, provided its liquefied product becomes available. Consequently, we propose that, in a patient with aspergilloma, the drug should be selected on the basis of MICs. This also seems to promote the therapy which requires both the lowest drug concentration and the smallest total dosage, leading to safe and efficient antifungal chemotherapy. Further examinations with a larger number of patients will be necessary to substantiate this conclusion.
